Clinical trial
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
NCT00930553 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2009
- Completion date
- February 29, 2016
- Enrollment
- 1,314 (actual)
- Sites
- 176
Conditions
As the registry lists them; a condition with its own page is linked.